Login to Your Account

Other News To Note

Monday, November 28, 2011
• Cipher Pharmaceuticals Inc., of Mississauga, Ontario, submitted an amendment to its pending new drug application to the FDA for cip-isotretinoin, which is in development for the treatment of acne. The amendment includes additional clinical information requested by the FDA. Acceptance by the FDA as a complete response will trigger a $1 million milestone payment from Cipher's marketing partner.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription